CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis

• Main Authors: Olaf Sommerburg (Author), Susanne Hämmerling (Author), S. Philipp Schneider (Author), Jürgen Okun (Author), Claus-Dieter Langhans (Author), Patricia Leutz-Schmidt (Author), Mark O. Wielpütz (Author), Werner Siems (Author), Simon Y. Gräber (Author), Marcus A. Mall (Author), Mirjam Stahl (Author)
• Format: Book
• Published: MDPI AG, 2021-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Rationale: Cystic fibrosis (CF), caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, leads to impaired pancreatic function and therefore reduced intestinal absorption of lipids and fat-soluble vitamins especially in patients with CF developing pancreatic insuf...